• Explore /
  • Poster
  • / TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA

Toni K. Choueiri , Laurence Albiges , Hans J. Hammers , Rana R. McKay , Daniel Yick Chin Heng , Katy Beckermann , Vijay Kasturi , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04987203

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS405)

DOI

10.1200/JCO.2022.40.6_suppl.TPS405

Abstract #

TPS405

Poster Bd #

M7

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Douglas Adkins

First Author: Corinne Maurice-Dror

First Author: Sumanta K. Pal